Triplex DNA-mediated downregulation of Ets2 expression results in growth inhibition and apoptosis in human prostate cancer cells
- 3 August 2004
- journal article
- Published by Oxford University Press (OUP) in Nucleic Acids Research
- Vol. 32 (14), 4358-4367
- https://doi.org/10.1093/nar/gkh744
Abstract
Ets2 is a member of the Ets family of transcription factors that in humans comprise 25 distinct members. Various Ets-domain transcription factors have been implicated in cancer development. Ets2 is expressed in prostate and breast cancer cells and is thought to have a role in promoting growth and survival in these cell types. However, a definitive role and the mechan- isms whereby Ets2 acts in cancer cells are still unclear. Structural and functional similarities as well as overlapping DNA binding specificities compli- cate the identification of the specific roles of the various Ets factors. In this study, we used a triplex- forming oligonucleotide (TFO) to selectively inhibit Ets2 transcription in prostate cancer cells. We had previously shown that the Ets2-targeting TFO, which was directed to a unique purine-rich sequence critical for Ets2 promoter activity, acted with a high degree of sequence-specificity and target selectivity. TFO-mediated downregulation of Ets2 in prostate cancer cells induced important phenotypic changes, including inhibition of anchorage-dependent and anchorage -independent growth, cell cycle alterations and induction of apoptotic cell death. Expression of Ets2 under the control of a heterologous promoter abolished the anti-proliferative effects of the TFO in both short- and long-term assays, suggesting that these effects were a direct result of downregulation of Ets2 transcription and confirming target selectivity of the TFO. Furthermore, normal human fibroblasts, which expressed low levels of Ets2, were not affected by the Ets2-targeting TFO. Downregulation of Ets2 in prostate cancer cells was associated with reduced levels of the anti-apoptotic protein bcl-xL and growth regulatory factors cyclin D1 and c-myc. These data revealed a specific role of this transcription factor in promoting growth and survival of prostate cancer cells. Furthermore, the activity and selectivity of the Ets2-targeting TFO suggest that it might represent a valid approach to prostate cancer therapy.Keywords
This publication has 51 references indexed in Scilit:
- siRNAs: applications in functional genomics and potential as therapeuticsNature Reviews Drug Discovery, 2004
- Ets proteins in biological control and cancerJournal of Cellular Biochemistry, 2004
- G-rich Oligonucleotide Inhibits the Binding of a Nuclear Protein to the Ki-ras Promoter and Strongly Reduces Cell Growth in Human Carcinoma Pancreatic CellsBiochemistry, 2004
- Ets target genes: past, present and futureOncogene, 2000
- Signal transduction and the Ets family of transcription factorsOncogene, 2000
- Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasivenessOncogene, 2000
- ETS2 function is required to maintain the transformed state of human prostate cancer cellsOncogene, 1998
- Identification of differentially expressed prostate genes: Increased expression of transcription factor ETS-2 in prostate cancerThe Prostate, 1997
- Cancer Cell CyclesScience, 1996
- Progress in Antisense Oligonucleotide TherapeuticsAnnual Review of Pharmacology and Toxicology, 1996